Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Cardiometabolic risk control and the use of kidney-protective treatments are central to slowing CKD progression. Current guidelines emphasize four pillars of therapy: renin–angiotensin system inhibitors (RASi), sodium–glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RA), and non-steroidal mineralocorticoid receptor antagonists (ns-MRA). The ns-MRA were not yet available in Thailand during the study period. This study evaluated cardiometabolic control and the uptake of kidney-protective agents among Thai CKD patients.
Baseline data from the Thai CKD Project, ongoing prospective cohort study enrolling adults with CKD stages G3–G5 (eGFR ≤60 mL/min/1.73 m²) from 41 hospitals nationwide, were analyzed among patients with CKD G3–G5 (eGFR ≤ 60 mL/min/1.73 m²). Optimal control was defined as blood pressure (BP) <130 mmHg, HbA1c <7%, and LDL-cholesterol <100 mg/dL. Medication use, including RASi, statins, SGLT2i, and GLP-1RA, was examined overall, by diabetes status, and across KDIGO G×A categories. Prescription patterns were compared between academic medical centers and tertiary care hospitals, with statistical significance defined as p < 0.05.
Among 3,344 CKD participants (mean age 69 ± 12 years; 45% female; 50% with diabetes), cardiometabolic control remained modest: BP <130 mmHg in 39%, HbA1c <7% among those with diabetes in 59%, and LDL <100 mg/dL in 64%.Use of kidney-protective agents was: RASi 42%, statins 70%, SGLT2i 14% (28% among diabetes patients), and GLP-1RA 5.6%. RASi use declined with advanced CKD stage, whereas SGLT2i and GLP-1RA were prescribed mainly in diabetic patients with preserved eGFR. Treatment disparities across KDIGO G×A staging indicated a continued underutilization of SGLT2i and GLP-1RA, especially SGLT2i in non-diabetic patients and advanced CKD (Figure 1).
When comparing different types of hospitals, academic medical centers prescribed more antihypertensive, lipid-lowering, and kidney-protective medications, such as SGLT2i and GLP-1RA (p < 0.001). While tertiary hospitals achieved better BP control and showed greater NSAID use (p < 0.001). (Table 1)
Cardiometabolic control among Thai patients with CKD remains suboptimal, and the use of kidney-protective therapies such as SGLT2i and GLP-1RA is limited. Academic medical centers focus on pharmacological and nephroprotective strategies, while tertiary hospitals achieve better blood pressure control. Integrating these complementary strengths and enhancing access to nephroprotective medications may improve renal and cardiovascular outcomes nationwide.
